Targeting PCSK9 for Therapeutic Gains

Michael D. Shapiro, Sergio Fazio, Hagai Tavori

    Research output: Contribution to journalReview articlepeer-review

    19 Scopus citations


    Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both hypercholesterolemia and low cholesterol syndromes, a rich literature has developed describing its unique physiology and the impact of antagonism of this molecule on cholesterol metabolism for therapeutic purposes. Indeed, the PCSK9 story is unfolding rapidly, with many answers and more questions. This review summarizes the most recent data from phase II/III clinical trials of PCSK9 inhibition with the three leading antibodies, highlights the clinical significance of the ongoing studies, and suggests future areas of investigation based on recent basic science discoveries on the physiology of PCSK9.

    Original languageEnglish (US)
    JournalCurrent atherosclerosis reports
    Issue number4
    StatePublished - Apr 2015


    • Lipoprotein (a)
    • Low-density lipoprotein
    • Low-density lipoprotein receptor
    • Pleiotropic effects
    • Proprotein convertase subtilisin kexin 9
    • Triglycerdies

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine


    Dive into the research topics of 'Targeting PCSK9 for Therapeutic Gains'. Together they form a unique fingerprint.

    Cite this